Therapeutic effect of strontium fructose 1,6-diphosphate (Sr-FDP) on glucocorticoid-induced osteoporosis in rats

Journal of China Pharmaceutical University

Volumn 39, Issue 5, 2008, Pages 442-446

  Zhang, Qi ^a   Ma, Bo ^a   Bai, Wen Xia ^a   Cheng, Yan Ping ^a   Ying, Han Jie ^a  

^a NANJING TECH UNIVERSITY   (China)

Author keywords

Dexamethasone; Glucocorticoid; Osteoporosis; Strontium fructose 1,6 diphosphate (Sr FDP)

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AGENTS AFFECTING PROTEIN METABOLISM; ALKALINE PHOSPHATASE; DEXAMETHASONE; GLUCOCORTICOID; STRONTIUM FRUCTOSE 1,6 DIPHOSPHATE; STRONTIUM RANELATE; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BIOMECHANICS; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; DRUG EFFECT; FEMUR; LUMBAR VERTEBRA; MORPHOLOGY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; RAT; TRABECULAR BONE;

EID: 55749108830     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Christiansen C. Osteoporosis: diagnosis and management today and tomorrow[J]. Bone,1995,17(5 Suppl):513S-516s.
2. Barlow D. Strontium and osteoporosis [J]. J Br Menopause Soc, 2003,9(1):7.
3. Blake GM, Fogelman I. Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy[J]. Clin Interv Aging,2006,1(4):367-375.
4. Novak S. Strontium ranelate (Osseor)-unique double mechanism-physiologic bone treatment as live tissue[J]. Reumatizam,2007, 54(2):83-84.
5. Chinese source.
6. Mazziotti G, Giustina A, Canalis E. Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects[J]. Arq Bras Endocrinol Metabol,2007, 51(8):1 404-1 412.
7. (Jin WF), (Wang HF), (Gu SZ), (Chin J Osteoporos) 2004,10(4): 461-465.
8. Walker J. Osteoporosis: pathogenesis, diagnosis and management [J]. Nurs Stand,2008,22(17):48-56.
9. Nenonen A, Cheng S, Ivaska KK, et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover[J]. J Bone Miner Res,2005, 20(10):1 804-1 812.
10. (Zhang YY), (Lu CY), (Liu B). (Chin J Osteoporos) 2007,13(11):809-813.
11. Landi E, Tampieri A, Celotti G, et al. Sr-substituted hydroxyapatites for osteoporotic bone replacement[J]. Acta Biomater,2007, 3 (6):961-969.
12. Chinese source.